Titan Pharmaceuticals Inc
TTNPDelisted Oct 2, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000910267
Titan Pharmaceuticals Inc was delisted on Oct 2, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 18 institutions reported holding it in 13F filings for Q3 2025, worth $107.1K in total; no superinvestor held it.
13F holders, Q3 2023
Institutional positions in Titan Pharmaceuticals Inc as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +2 vs. Q2 2023
- Shares held
- 1.05M
- +76.3K (+7.8%) vs. Q2 2023
- Total value
- $497.8K
- −$134.9K (−21.3%) vs. Q2 2023
- New holders
- 5
- 5 more added
- Sold out
- 3
- 1 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TTNP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 5 | $69 |
| Q1 2026 | 6 | $130 |
| Q4 2025 | 4 | $154 |
| Q3 2025 | 18 | $107.1K |
| Q2 2025 | 20 | $158.3K |
| Q1 2025 | 17 | $51.9K |
| Q4 2024 | 15 | $9.41K |
| Q3 2024 | 16 | $88.5K |
| Q2 2024 | 18 | $179.3K |
| Q1 2024 | 17 | $230.0K |
| Q4 2023 | 24 | $408.2K |
| Q3 2023 | 27 | $497.8K |
| Q2 2023 | 25 | $632.7K |
| Q1 2023 | 22 | $787.4K |
| Q4 2022 | 23 | $757.9K |
| Q3 2022 | 21 | $1.14M |
| Q2 2022 | 24 | $371.0K |
| Q1 2022 | 24 | $1.24M |
| Q4 2021 | 24 | $430.0K |
| Q3 2021 | 22 | $722.0K |
| Q2 2021 | 23 | $1.51M |
| Q1 2021 | 24 | $988.1K |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Titan Pharmaceuticals Inc; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| St Germain D J Co Inc | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Cape Investment Advisory, Inc. | 1 | $0 | 0.00% | 00.0% | Unchanged |
| McClarren Financial Advisors, Inc. | 3 | $0 | 0.00% | +3 | New |
| Caldwell Sutter Capital, Inc. | 2 | $1 | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 2 | $1 | 0.00% | 00.0% | Unchanged |
| Nemes Rush Group LLC | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Westside Investment Management, Inc. | 4 | $2 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 4 | $2 | 0.00% | +4 | New |
| Qube Research & Technologies Ltd | 4 | $2 | 0.00% | +4 | New |
| Morgan Stanley | 16 | $8 | 0.00% | 00.0% | Unchanged |
| Global Wealth Strategies & Associates | 40 | $19 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 50 | $22 | 0.00% | +13+35.1% | Added |
| BlackRock Inc. | 60 | $28 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 62 | $29 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 84 | $40 | 0.00% | +1+1.2% | Added |
| JPMorgan Chase & Co | 157 | $73 | 0.00% | +96+157.4% | Added |
| Bank of America Corp | 206 | $97 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 230 | $107 | 0.00% | −100−30.3% | Reduced |
| Level Financial Advisors, Inc. | 987 | $468 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,573 | $746 | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 19,705 | $9.34K | 0.00% | +19,705 | New |
| State Street Corp | 38,287 | $17.8K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 62,145 | $28.9K | 0.00% | +62,145 | New |
| Vanguard Group Inc | 82,051 | $38.9K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 87,945 | $40.9K | 0.00% | +23,980+37.5% | Added |
| Renaissance Technologies LLC | 135,710 | $64.0K | 0.00% | +100+0.1% | Added |
| Truist Financial Corp | 625,089 | $296.3K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −29,675−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |